Screener
Supernus Pharmaceuticals SUPN Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net product sales | $150,753 | $141,988 |
| Collaboration revenue (ZURZUVAE) | 27,643 | — |
| Royalty, licensing, and other revenues | 29,309 | 7,836 |
| Total revenues | 207,705 | 149,824 |
| Costs and expenses | ||
| Cost of revenues(a) | 23,391 | 15,763 |
| Research and development | 39,438 | 26,927 |
| Selling, general and administrative | 125,173 | 89,944 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's total revenue?
- Supernus Pharmaceuticals (SUPN) reported total revenue of $207.71M in Q1 2026.
- How has Supernus Pharmaceuticals's total revenue changed year-over-year?
- Supernus Pharmaceuticals's total revenue increased by 38.6% year-over-year, from $149.82M to $207.71M.
- What is the long-term trend for Supernus Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's total revenue has grown at a 5.5% compound annual growth rate (CAGR), from $579.78M to $718.95M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Supernus Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude